Core Viewpoint - BioMarin Pharmaceutical has decided to discontinue mid-stage trials of its bone disorder treatment Voxzogo due to reports of patients experiencing hip joint issues, leading to a 4% drop in its share price [1]. Group 1: Treatment and Trials - BioMarin was testing Voxzogo in patients with Turner Syndrome, SHOX-deficiency, and ACAN-deficiency, which are genetic conditions associated with severe short stature and abnormal bone development [2]. - During the trials, several patients experienced slipped capital femoral epiphysis, a condition where the hip joint's ball slips off the thigh bone [3]. - Despite halting trials for certain conditions, BioMarin will continue testing Voxzogo in patients with Noonan syndrome and unexplained short stature [3]. Group 2: Regulatory Background - The U.S. FDA approved Voxzogo in 2021 for patients with achondroplasia, a type of dwarfism [4]. - Recently, the FDA also approved Ascendis Pharma's Yuviwel, marking it as the second treatment for achondroplasia to receive U.S. approval [4].

Core Insights - The FDA has granted multiple approvals for new treatments across various therapeutic areas, including oncology and rare genetic disorders, in late February and early March 2026 Group 1: Boehringer Ingelheim Pharmaceuticals Inc. - The FDA granted accelerated approval to Hernexeos as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with HER2 mutations on February 26, 2026 [2] - Hernexeos is the first targeted therapy for HER2-mutant advanced NSCLC in the first-line setting, with HER2 mutations occurring in approximately 2-4% of NSCLC cases [3] Group 2: Ascendis Pharma A/S - Ascendis received accelerated approval for Yuviwel, a once-weekly treatment for children aged 2 years and older with achondroplasia on February 27, 2026 [4] - Yuviwel is the first and only approved therapy providing continuous systemic exposure to C-type natriuretic peptide (CNP) over a weekly dosing interval [6] Group 3: BioMarin Pharmaceutical Inc. - BioMarin expanded the indication of Palynziq to include pediatric patients aged 12 years and older with phenylketonuria (PKU) on February 27, 2026 [7] - Palynziq is the only enzyme substitution therapy approved to reduce blood phenylalanine concentrations in PKU patients, generating $433 million in revenue in 2025, up from $355 million in 2024 [9] Group 4: Novo Nordisk A/S - Novo Nordisk received FDA approval for three new indications for Sogroya, a long-acting growth hormone, on February 27, 2026 [10] - Sogroya is now approved for children aged 2.5 years and older with Idiopathic Short Stature, short stature born Small for Gestational Age, and growth failure associated with Noonan Syndrome [11] - The once-weekly administration of Sogroya aims to improve adherence compared to daily growth hormone injections [12] Group 5: Johnson & Johnson - The FDA approved Tecvayli plus Darzalex Faspro for adults with relapsed or refractory multiple myeloma on March 5, 2026 [13] - Tecvayli received accelerated approval in October 2022 as a subcutaneous treatment for patients with RRMM who have undergone multiple prior therapies [14] - Darzalex Faspro is already approved for multiple indications in multiple myeloma, enhancing treatment options for patients [15]

Core Insights - The Growth Stock Forum focuses on identifying attractive growth stocks, particularly in the biotech sector, emphasizing risk/reward situations [1] - The biotech Top Picks of the forum achieved a remarkable increase of 137.6% last year, with a compound annual growth rate (CAGR) of 37.2% since 2017 [1] - The core portfolio, LTGP, has also demonstrated strong performance with a mid-20s CAGR as of February 20, 2026 [1]

Core Viewpoint - Ascendis Pharma A/S has received an upgrade from Evercore ISI to "Outperform" with a price target of $324, driven by the FDA's approval of its innovative therapy Yuviwel for achondroplasia in children [1][6]. Group 1: Company Overview - Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases [1]. - The company's current stock price is approximately $233, with a market capitalization of around $14.3 billion [4]. Group 2: Product Development - The FDA approved Yuviwel, a once-weekly treatment for children with achondroplasia, based on data from three randomized clinical trials [2]. - Yuviwel is the first therapy designed to enhance linear growth in children aged two years and older, marking a significant advancement in treatment options for this rare genetic disorder [2][3]. Group 3: Regulatory Milestones - The approval of Yuviwel under the FDA's Accelerated Approval Program is a major milestone for Ascendis Pharma, emphasizing the therapy's importance [3]. - The company has also received a Rare Pediatric Disease Priority Review Voucher, further highlighting the significance of Yuviwel [3]. Group 4: Market Performance - The stock of ASND has shown fluctuations, with a trading volume of 602,078 shares, indicating strong investor interest [5]. - The stock has a 52-week high of $242 and a low of $124.06, reflecting its volatility in the market [5].